Wallingford, CT, United States of America

Kyle E Parcella

USPTO Granted Patents = 24 

 

Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 94(Granted Patents)


Location History:

  • Wallingford, CT (US) (2011 - 2020)
  • Branford, CT (US) (2022 - 2023)

Company Filing History:


Years Active: 2011-2023

Loading Chart...
Loading Chart...
24 patents (USPTO):

Title: The Innovative Contributions of Kyle E. Parcella

Introduction: Kyle E. Parcella, based in Wallingford, Connecticut, has made significant strides in the field of pharmaceutical innovation. With a remarkable portfolio of 24 patents, Parcella has dedicated his career to developing compounds that aim to combat critical health issues, particularly human immunodeficiency virus (HIV) infection.

Latest Patents: Among his noteworthy contributions to the scientific community are his recent patents focused on inhibitors of HIV replication. These include compounds outlined in his patents, particularly the 4-oxo-3,4-dihydroquinazoline compounds, which consist of pharmaceutically acceptable salts and various compositions and methods designed for treating HIV infections. His work represents a pivotal step forward in the search for effective treatments against this pervasive virus.

Career Highlights: Throughout his career, Kyle E. Parcella has worked with leading pharmaceutical companies such as Bristol-Myers Squibb Company and ViiV Healthcare UK (No.5) Limited. His role in these organizations has allowed him to pioneer advancements in drug development and contribute substantially to public health.

Collaborations: The impact of Parcella's work is also reflected in his collaborations with esteemed colleagues in the field. Notable figures, such as John F. Kadow and Kap-Sun Yeung, have collaborated with him, demonstrating the importance of teamwork in advancing the science of pharmaceuticals.

Conclusion: Kyle E. Parcella's innovative contributions and robust intellectual property portfolio underscore his valuable role in the fight against HIV. His expertise and collaborative efforts in the pharmaceutical sector continue to pave the way for new therapies that could greatly benefit patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…